Bioengineering Distinguished Seminar: Douglas Lauffenburger

Friday, April 15, 2016
9:00 a.m.-10:00 a.m.
Room 2108, Chemical and Nuclear Engineering Building
Dr. Christopher Jewell
cmjewell@umd.edu

Dr. Douglas Lauffenburger
Ford Professor and Department Head
Department of Biological Engineering
Massachusetts Institute of Technology

Systems Biology Approaches to Current Problems in Cancer Therapeutics

Systems Biology is an area of biomedical science incorporating substantial contributions from bioengineering and continuing to increase in influence and impact.  In this seminar, I will present a few examples of recent work from our laboratory that demonstrate new insights being gained from application of systems biology approaches to current major problems in cancer therapeutics – these include drug resistance, tumor heterogeneity, and microenvironment effects.  These examples will exhibit deep integration of quantitative multi-variate experiment and computational modeling.


About the Speaker

Douglas A. Lauffenburger is Ford Professor of Bioengineering and (founding) Head of the Department of Biological Engineering at MIT.  Professor Lauffenburger also holds appointments in the Department of Biology and the Department of Chemical Engineering, is a member of the Center for Biomedical Engineering, Center for Environmental Health Sciences, Center for Gynepathology Research, and Koch Institute for Integrative Cancer Research. 

Dr. Lauffenburger’s BS and PhD degrees are in chemical engineering from the University of Illinois and the University of Minnesota, in 1975 and 1979 respectively.  His major research interests are in cell engineering: the fusion of engineering with molecular cell biology. A central focus of his research program is in receptor-mediated cell communication and intracellular signal transduction, with emphasis on development of predictive computational models derived from quantitative experimental studies, for cell cue/signal/response relationships important in pathophysiology with application to drug discovery and development.  Lauffenburger has co-authored a monograph entitled Receptors: Models for Binding, Trafficking & Signaling, published by Oxford University Press in 1993; he has also co-edited the book entitled Systems Biomedicine: Concepts and Perspectives, published by Elsevier in 2010.  More than 100 doctoral students and postdoctoral associates have undertaken research education under his supervision.

Prof. Lauffenburger has served as a consultant or scientific advisory board member for Astra-Zeneca, Beyond Genomics, CellPro, Complete Genomics, Eli Lilly, Entelos, Genentech, Johnson & Johnson, Merck, Merrimack, Pfizer, the Burroughs-Wellcome Fund, and the Whitaker Foundation.  His awards include the Pierre Galletti Award from AIMBE, the A.P. Colburn Award, Bioengineering Division Award, and W.H. Walker Award from AIChE, the Distinguished Lecture Award and the Shu Chien Lifetime Achievement Award from BMES, the C.W. McGraw Award from ASEE, the Amgen Award in Biochemical Engineering from the Engineering Foundation, and a J.S. Guggenheim Fellowship, along with a number of named lectures at academic institutions.  He is a member of the National Academy of Engineering and the American Academy of Arts & Sciences, and has served as President of the Biomedical Engineering Society, Chair of the College of Fellows of American Institute for Medical & Biological Engineering, and on the Advisory Council for NIGMS, and as a co-author of the 2009 NRC report on A New Biology for the 21st Century.

 

Audience: Public 

remind we with google calendar

 

March 2024

SU MO TU WE TH FR SA
25 26 27 28 29 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31 1 2 3 4 5 6
Submit an Event